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SUMMARY  
Obestatin is a 23-amino acid C-terminally amidated gastrointestinal peptide derived from 
preproghrelin and which forms an alpha helix. Although obestatin has a short biological half-
life and is rapidly degraded, it is proposed to exert wide-ranging pathophysiological actions. 
Whilst the precise nature of many of its effects is unclear, accumulating evidence supports 
positive actions on both metabolism and cardiovascular function. For example, obestatin has 
been reported to inhibit food and water intake, body weight gain, and gastrointestinal motility, 
and to also mediate promotion of cell survival and prevention of apoptosis. Obestatin-induced 
increases in β-cell mass, enhanced adipogenesis and improved lipid metabolism have been 
noted along with upregulation of genes associated with β-cell regeneration, insulin production 
and adipogenesis. Furthermore, human circulating obestatin levels generally demonstrate an 
inverse association with obesity and diabetes, whilst the peptide has been shown to confer 
protective metabolic effects in experimental diabetes, suggesting that it may hold therapeutic 
potential in this setting. Obestatin also appears to be involved in blood pressure regulation and 
to exert beneficial effects on endothelial function, with experimental studies indicating that it 
may also promote cardioprotective actions against, for example, ischaemia-reperfusion injury. 
This review will present a critical appraisal of the expanding obestatin research area and discuss 
the emerging therapeutic potential of this peptide for both metabolic and cardiovascular 
complications of diabetes. 
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ABBREVIATIONS:   
BKCa, large conductance calcium-activated potassium channel; cAMP, cyclic adenosine 
monophosphate; CART, cocaine and amphetamine-related transcript; C/EBP, CCAAT-
enhancer-binding protein; CCK, cholecystokinin; CRF, corticotrophin releasing factor; EIA, 
enzyme immunoassay; ERK, extracellular signal-regulated kinase; GI, gastrointestinal; GLP-
1, glucagon-like peptide-1; GLP-1R, glucagon-like peptide-1 receptor; GLUT-4, glucose 
transporter type 4; GPR39, G-protein coupled receptor 39; GSK-3β, glycogen synthase kinase-
3β; HOMA-IR, homeostatic model assessment of insulin resistance; LDL, low-density 
lipoprotein; MCP-1, monocyte chemoattractant protein-1; mTOR, mechanistic target of 
rapamycin; NO, nitric oxide; NPY, neuropeptide Y; PEG, polyethylene glycol; PI3K, 
phosphoinositide 3-kinase; PKC, protein kinase C; POMC, proopiomelanocortin; PPAR, 
peroxisome proliferator-activated receptor; RIA, radioimmunoassay; SK61, ribosomal protein 
S6 kinase 1; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus; TNF-α, tumour 
necrosis factor-α; VCAM-1, vascular cell adhesion molecule-1; VEGF, vascular endothelial 
growth factor; WAT, white adipose tissue. 
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INTRODUCTION 
Currently 415M adults are thought to have diabetes worldwide, with an increasing 
number developing obesity-related type 2 diabetes mellitus (T2DM) at a typically younger age. 
More worryingly, this figure is rapidly rising to epidemic proportions and is estimated to reach 
642M by 2040 (International Diabetes Federation, 2015). The disease itself is a leading cause 
of global mortality, accounting for 5M adult deaths in 2015, with the major underlying factor 
being cardiovascular disease due to common complications, such as atherosclerosis, 
nephropathy, and stroke, which confer a 4-fold increased risk of death (Grundy et al., 1999). 
This is despite optimal management with established metabolic and cardiovascular therapies, 
including metformin and angiotensin-converting enzyme inhibitors. Although there have been 
some recent advances in the development of novel anti-diabetic agents, such as drugs targeting 
the glucagon-like peptide-1 (GLP-1) receptor, the potential cardiovascular benefits of such 
therapies remain controversial (Tate et al., 2015). The need for improved treatment strategies 
which improve both the metabolic profile and cardiovascular risk in diabetic patients is 
therefore clear. In this regard, this article will focus on obestatin, a recently discovered 
endogenous peptide with emerging metabolic and cardiovascular actions which may be relevant 
to T2DM. Whilst previous reviews have tended to highlight the pathophysiological actions of 
obestatin in relation to its well characterised sister hormone, ghrelin, we will specifically focus 
on the somewhat controversial metabolic effects of obestatin and discuss these together with its 
emerging cardiovascular actions in order to provide a balanced up-to-date critical appraisal of 
this developing research area with a view towards potential therapeutic applications. 
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BIOLOGY OF OBESTATIN 
Obestatin discovery 
First discovered in 2005 using bioinformatics, obestatin is a 23-amino acid peptide 
which is derived from the same 117-residue prepropeptide as ghrelin (Zhang et al., 2005). It 
displays a post-translational amide modification of the C terminal, which was initially 
suggested to be essential for binding of obestatin (Zhang et al., 2005), and later demonstrated 
to be essential for stabilisation of the peptide in to its regular conformation  (Scrima et al., 
2007), which has now been determined. Detailed analysis using nuclear magnetic resonance 
and circular dichroism spectroscopy found that both human and mouse obestatin, as well as 
fragments of human obestatin: (6-23), (11-23) and (16-23), adopted an α-helical secondary 
structure despite their different sequences (Alen et al., 2012). It seems likely that this 
characteristic structure is required for binding of obestatin to its receptor, although the specific 
domains involved remain to be determined. Subsequent to its initial discovery, the receptor for 
obestatin was reported to be the G-protein coupled receptor 39 (GPR39) (Zhang et al., 2005), 
although this has been highly disputed (Lauwers et al., 2006), with zinc ions appearing to be 
the endogenous ligand for this receptor (Holst et al., 2007; Popovics and Stewart, 2011). In 
support of this, gene-modified mice lacking GPR39 displayed a similar metabolic profile e.g. 
food intake, body weight, adiposity, fasting glucose/insulin (which are modified by obestatin; 
see below), compared to wild-type controls, and an intact metabolic response to obestatin, 
providing strong evidence that GRP39 is not the native receptor for obestatin, at least in the 
gastrointestinal (GI) tract (Tremblay et al., 2007). However, another group reported increased 
gastric emptying in the same GPR39-/- mice (Moechars et al., 2006), thereby supporting the 
initial findings (Zhang et al., 2005). Indeed, more recent studies have indicated that obestatin 
upregulates GPR39 in isolated rat adipocytes and mouse white adipose tissue (WAT), where it 
may mediate at least some of its reported effects via induction of c-Fos and extracellular signal-
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regulated kinase (ERK) 1/2 signalling (Zhang et al., 2008a; Pruszynska-Oszmalek et al., 2013; 
Ren et al., 2013a). Further to several similarities between the emerging actions of obestatin (see 
below) and those of GLP-1, particularly in relation to pancreatic β-cells, the GLP-1 receptor 
(GLP-1R) was suggested as a candidate for the obestatin receptor. Indeed, obestatin was shown 
to bind and upregulate the GLP-1R and its effects on β-cell survival were attenuated by the 
GLP-1R antagonist, exendin(9-39) (Granata et al., 2008). Furthermore, in mouse 3T3-L1 and 
human adipocytes both activation and blockade of the GLP-1R inhibited obestatin binding 
(Granata et al., 2012). In contrast, obestatin was unable to bind to the GLP-1R or to displace 
GLP-1 binding in INS-1 pancreatic β-cells and HEK293 cells overexpressing GLP-1R 
(Unniappan et al., 2008). Taken together, these data are generally supportive of the suggestion 
that obestatin may signal through the GLP-1R, although there is currently insufficient 
independently-verified evidence to allow definite conclusions to be drawn. Nonetheless, the 
prospect of involvement of the GLP-1R in obestatin signalling is particularly intriguing further 
to our recent reports of direct cardioprotective actions of GLP-1R activation (Robinson et al. 
2015; Tate et al. 2016). In this regard, we have suggested that obestatin may signal via an 
adenylate cyclase-linked G protein-coupled receptor in the cardiovascular system (Agnew et al. 
2012), although the precise identity of the cognate receptor(s) for obestatin remains to be 
determined. Indeed, it is likely that the obestatin receptor may vary between tissues, and 
detailed biochemical analysis using, for example, binding studies with putative orphan 
receptors or ligand-based affinity chromatography (Pattnaik, 2005), will be required in order to 
gain a clearer understanding of its signalling. 
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Tissue distribution 
Obestatin and ghrelin are largely produced throughout the GI tract (e.g. stomach, 
pancreas, duodenum) with predominant expression in the gastric mucosa (Zhao et al., 2008), 
although their distribution is somewhat species-specific. For example, in the rat, obestatin is 
found in the GI tract, within the A-like cells and oxyntic glands of the gastric mucosa and 
cholinergic neurons of the myentric plexus, and in the Leydig cells of the testis where it is co-
localised with its precursor peptide, preproghrelin (Zhao et al., 2008; Mizutani et al., 2009). 
Obestatin is also expressed in the brain where it promotes calcium signalling via stimulation of 
intracellular calcium store release (Ku et al., 2015), which may mediate some of its proposed 
central actions (see below). In rodents, ghrelin is reported to be present in the GI mucosa  (Dun 
et al., 2006), and is also expressed by cholinergic neurons of the myenteric plexus (Xu et al., 
2005). Similarly, in humans, the majority of obestatin production is localised to the GI tract, 
with predominance in the stomach versus the duodenum, jejunum and ileum (where it is 
specifically found in the crypts of Lieberkuhn and Brunner's glands), and absence from the 
colon, whilst obestatin is also expressed in both the periphery of the pancreatic islets and the 
exocrine pancreatic ducts (Grönberg et al., 2008). Furthermore, both obestatin and ghrelin have 
been identified in epithelial ducts of the human mammary gland (Grönberg et al., 2008), with 
ghrelin-positive cells found in some human breast cancers and cell lines (Cassoni et al., 2004). 
In contrast, there are conflicting reports with regard to obestatin/ghrelin co-expression, with 
one study reporting a high degree of co-localisation in human cells (Grönberg et al., 2008), 
whereas another found that only 60% of obestatin immunoreactive cells were also 
immunoreactive for ghrelin (Zhao et al., 2008). However, it should be noted that these 
differences may be explained by variations in detection or sensitivity between the two studies. 
 
Stability of obestatin and circulating levels 
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Once obestatin enters the circulation, it is rapidly degraded by a number of proteases, 
such as aminopeptidase and post-prolyl endopeptidase, which are largely located in the blood, 
liver and kidney (Vergote et al., 2008). Its half-life in the plasma is a critical determinant of 
whether obestatin is able to reach and act upon its target tissues, and published figures in rodents 
are highly variable. For example, the half-life of native mouse obestatin in mouse plasma is 
reported to be 42.2 minutes, compared with 12.6 minutes in liver and 138 minutes in kidney 
membranes (Vergote et al., 2008), whilst the half-life of rodent obestatin in rat liver homogenate 
was found to be 21.7 minutes, and increased over 3-fold by the addition of a polyethylene glycol 
(PEG) group to the N-terminus (Agnew et al., 2011). A large number of groups have 
investigated circulating physiological levels of obestatin in both rodents and humans, with a 
wide range of values reported (rodents: 1.34 to 2,560; humans: 8.4 to 22,057 pg/ml; see Table 
1). The most likely explanation for these markedly different results is due to variations in the 
sensitivity of the employed detection methods and their specificity for obestatin versus 
proghrelin (Seim et al., 2011). Interestingly, one group reported human plasma obestatin levels 
of 267±10 pg/mL (Zamrazilová et al., 2008), whilst another published values of 68.3±14.8 
pg/mL (Monteleone et al., 2008b), i.e. 4-fold lower, despite using the apparently same detection 
method. However, these differences may also be due to diurnal variations in obestatin 
production, which has been reported to follow a pulsatile pattern comparable to that of ghrelin 
(Zizzari et al., 2007). Such observations highlight the importance of following rigorous 
sampling and analysis protocols in order to achieve reliable estimates of circulating obestatin 
levels, which to date have been both conflicting and largely uninformative. 
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METABOLIC ACTIONS OF OBESTATIN 
Obestatin and the gastrointestinal system  
Further to its original discovery, obestatin was first reported to inhibit jejunal 
contraction, food intake and body weight gain in rats, in addition to antagonising ghrelin-
induced contraction of isolated jejunum muscle (Zhang et al., 2005), actions which are clearly 
relevant to T2DM. These initial findings with regard to GI transit have since been confirmed 
by the same authors (Zhang et al., 2007) and others, who have reported obestatin to reduce 
antral and duodenal motility in the fed state and to impede restoration of normal fasted state 
duodenal activity (Ataka et al., 2008; Fujimiya et al., 2008; Fujimiya et al., 2012). Decreased 
duodenal and jejunal motility in adult rats have also been confirmed by a recent study although 
increased GI contractility was demonstrated in suckling and adolescent rats in response to 
obestatin in this same investigation (Słupecka et al., 2014). Furthermore, a clinical investigation 
reported increased preprandial obestatin levels in children with unexplained delayed gastric 
emptying (Saliakelis et al., 2014). However, a significant number of investigators have failed 
to reproduce such effects of obestatin on GI motility (Bassil et al., 2007; De Smet et al., 2007; 
Gourcerol and Taché, 2007; Gourcerol et al., 2007a; Yamamoto et al., 2007; Chen et al., 2008, 
2010, 2012a, 2012b; Depoortere et al., 2008). Furthermore, obestatin is incapable of preventing 
ghrelin-mediated acceleration of gastric emptying or intestinal motility (Bassil et al., 2007; 
Ataka et al., 2008), and obestatin levels and the ghrelin/obestatin ratio are unchanged in patients 
with gastroparesis, a condition assoiated with delayed gastric emptying (Harsch et al., 2009), 
thereby challenging the proposed actions of obestatin on GI motility. Obestatin 
immunoreactivity in the stomach has also been questioned (Bang et al., 2007). Similarly, the 
originally-reported beneficial effects of obestatin on food intake and body weight have also 
been questioned, with more studies disputing (Seoane et al., 2006; Sibilia et al., 2006; Gourcerol 
et al., 2006, 2007a, 2007b; Nogueiras et al., 2007; Tremblay et al., 2007; Yamamoto et al., 
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2007; Zizzari et al., 2007; Gourcerol and Taché, 2007; Holst et al., 2007; Kobelt et al., 2008; 
Mondal et al., 2008; Unniappan et al., 2008; Depoortere et al., 2008; Van Dijck et al., 2009; 
Agnew et al., 2011; Ren et al., 2013a; Yuan et al., 2015) rather than confirming the initial 
findings (Bresciani et al., 2006; Green et al., 2007; Nagaraj et al., 2008, 2009; Brunetti et al., 
2009, 2010; Hassouna et al., 2012) on feeding behaviour. Notably, within these negative 
studies, obestatin was found not to influence cholecystokinin (CCK)-mediated satiety signalling 
(Gourcerol et al., 2006) and to inhibit water more potently than food intake, leading the authors 
to suggest that previously reported effects of obestatin on food intake may occur secondary to 
those on water intake (Samson et al., 2007), although these data have not been reproduced by 
other groups (Van Dijck et al., 2009; Agnew et al., 2011). Similarly, despite demonstrating 
significant effects of obestatin administration on food intake in rats in response to 24-hour food 
and water deprivation, a recent study reported no effects on water intake (Motorykina et al., 
2015).  
Further to its apparent, albeit controversial, effects on GI motility, food intake and body 
weight, obestatin has also been reported to modulate the actions of its sister hormone, ghrelin. 
For example, obestatin was shown to inhibit the orexigenic actions of ghrelin in rodents and 
fish (Zizzari et al., 2007; Yuan et al., 2015), although some groups found no effect (Seoane et 
al., 2006; Nogueiras et al., 2007). Furthermore, although obestatin did not affect brain 
expression of neuropeptide Y (NPY) and its receptors, agouti-related peptide, 
proopiomelanocortin (POMC), cocaine and amphetamine-related transcript (CART) and CCK 
in rodents, which are all involved in regulation of food intake (Nogueiras et al., 2007; Yuan et 
al., 2015), it was able to inhibit ghrelin-induced expression of NPY and NPY receptors, but not 
POMC, CART or CCK (Yuan et al., 2015). Notably, both native obestatin and a natural 
obestatin variant (preproghrelin polymorphism Gln90Leu) decreased ghrelin-induced food 
intake in mice, together with growth hormone secretion and c-Fos activation in the brain 
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(Hassouna et al., 2012). Conversely, obestatin-mediated decreases in GI motility were 
prevented by injection of corticotrophin releasing factor (CRF) receptor antagonists, whilst c-
Fos expression was induced by obestatin administration, indicating that potential actions on 
food intake and GI motility may occur, at least in part, via the vagal afferent pathway and central 
CRF receptors (Ataka et al., 2008; Fujimiya et al., 2008; Zhang et al., 2008a; Fujimiya et al., 
2012). 
In addition to its proposed physiological actions, it appears that obestatin may also 
confer some benefits in GI disease. For example, in rats, obestatin protects against experimental 
ulcerative colitis via acute attenuation of lipid peroxidation and TH1-mediated inflammation, 
chronic suppression of polymorphonuclear leukocyte infiltration, induction of glutathione 
synthesis, improved mucosal blood flow and stimulation of cell proliferation in colonic mucosa, 
effects which may be mediated by activation of anti-inflammatory cytokines (Pamukcu et al., 
2013; Matuszyk et al., 2015). Furthermore, obestatin administration has been shown to confer 
protective effects against ischaemia-reperfusion injury in rat ileum (Şen et al., 2015), whilst the 
ghrelin/obestatin ratio (but not obestatin levels) are reported to be elevated in patients with 
active inflammatory bowel diseases (Crohn’s disease and colitis) compared to those in 
remission (Jung et al., 2015; Alexandridis et al., 2009), suggesting that obestatin signalling may 
play a role in this setting. 
 
Obestatin and the pancreas 
Pancreatic β-cell loss, reduced β-cell function, and inflammation are characteristic of 
both type 1 diabetes mellitus (T1DM) and T2DM and so are a major focus of research aimed at 
development of novel metabolic therapies (Donath and Halban, 2004).  Indeed, obestatin and 
ghrelin are co-expressed in both foetal and adult endocrine pancreas with co-localisation at the 
islet periphery, thereby suggesting a synergistic relationship which may be connected with 
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pancreatic β-cell function (Granata et al., 2010a). In 2008, obestatin was reported to be secreted 
by human pancreatic islets and pancreatic β-cell lines, to enhance their viability in response to 
both serum starvation and cytokines, and to inhibit apoptosis (Granata et al., 2008; Favaro et 
al., 2012). In addition, survival of these cells was compromised upon incubation with an anti-
obestatin antibody, whilst genes associated with insulin production, β-cell survival, mass, 
growth and differentiation (insulin receptor substrate 2, cyclic adenosine monophosphate 
(cAMP) response element binding protein, pancreatic and duodenal homeobox-1, glucokinase) 
were upregulated by obestatin, together with activation of phosphoinositide 3-kinase 
(PI3K)/Akt, ERK1/2 and cAMP production (Granata et al., 2008), thus highlighting a potential 
autocrine/paracrine role. Obestatin also enhances generation of pancreatic islet-like clusters 
together with increased insulin gene expression during endocrine pancreatic precursor cell 
selection and differentiation, which appears to occur via pathways involving fibroblast growth 
factor receptors, notch receptors and neurogenin 3, suggesting a role in pancreatic development 
and regeneration (Baragli et al., 2013). Notably, the reported anti-apoptotic actions of obestatin 
in the pancreas appear to extend to its microvascular endothelial cells, indicating that such 
protection may be mediated indirectly via support of islet vascularisation (Favaro et al., 2012). 
Similarly, obestatin has been shown to protect against acute pancreatitis in rats, induced by 
either cerulein or ischaemia/reperfusion, via increasing pancreatic blood supply in parallel with 
reduced inflammation and digestive enzyme activity, and also to promote pancreatic repair and 
regeneration in these animals (Ceranowicz et al., 2009; Bukowczan et al., 2015). Indeed, 
circulating obestatin levels are increased in patients with acute pancreatitis (Kanat et al., 2014), 
supporting a protective function in this setting. 
Although obestatin appears to activate pancreatic insulin gene expression, at least in 
vitro, its effects on insulin secretion are unclear due to highly variable reports (Green et al., 
2007; Granata et al., 2008; Qader et al., 2008; Ren et al., 2008). For example, several studies 
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have shown obestatin to have no effect on circulating glucose or insulin in normoglycaemic 
mice and rats (Green et al., 2007; Kiewiet et al., 2008; Unniappan et al., 2008; Agnew et al., 
2011), although glucose-induced insulin secretion in rats in vivo and in mouse and rat isolated 
islets was inhibited by obestatin (Qader et al., 2008; Ren et al., 2008), which is consistent with 
reports of an inverse relationship between obestatin and insulin levels in humans (Gao et al., 
2008; Lippl et al., 2008). In contrast, other studies have shown obestatin to stimulate insulin 
secretion in human islets in both the presence and absence of glucose and to potentiate the 
insulinotropic actions of arginine and tolbutamide (Granata et al., 2008; Egido et al., 2009). 
Interestingly, obestatin is capable of regulating secretion of other pancreatic hormones 
(glucagon, pancreatic polypeptide, somatostatin) in isolated rodent islets (Qader et al., 2008) 
and increases pancreatic protein output in rats via vagal activation (Kapica et al., 2007). 
Although the precise pancreatic actions of obestatin remain unclear, the presented evidence 
highlighting beneficial effects on β-cell metabolism and survival coupled with its ability to 
modulate insulin levels and inflammation clearly supports further investigation of this peptide 
as a potential therapeutic target in diabetes.  
 
Obestatin and adipose tissue  
Similar to the gastrointestinal and pancreatic actions of obestatin, its reported effects on 
adipose tissue function, production and survival are also subject to some debate. Several groups 
have demonstrated obestatin secretion from rat WAT and adipocytes from both mice and 
humans (Gurriarán-Rodríguez et al., 2011b; Granata et al., 2012), although one study implied 
that adipose tissue does not secrete obestatin (Zhang et al., 2008b). Expression of the obestatin 
precursor, preproghrelin, has also been reported in mouse epididymal and subcutaneous adipose 
tissue, whilst both neutralisation of preproghrelin protein products (including obestatin) and 
inhibition of preproghrelin gene expression, decrease adipocyte differentiation (Granata et al., 
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2012). In addition to its secretion, obestatin may mediate important actions on adipose tissue 
(see below), pointing towards a potential autocrine/paracrine role (Gurriarán-Rodríguez et al., 
2011a). Indeed, adipose tissue is considered to be endocrine in nature, further to adipokine-
mediated regulation of glucose, lipid and energy homeostasis, as well as inflammation. Notably, 
obesity and deregulation of these processes, which appear to be modulated by obestatin, are 
frequently associated with insulin resistance and diabetes (Hotamisligil, 2006; Xin et al., 2009; 
Galic et al., 2010; Guilherme et al., 2010). 
Specifically, obestatin is reported to improve survival and inhibit apoptosis of 3T3-L1 
preadipocytes via stimulation of ERK1/2 and P13K/Akt, which are established mediators of 
adipocyte proliferation and survival (Miegueu et al., 2011; Granata et al., 2012), and to increase 
adipogenesis of these cells as well as that of human omental and subcutaneous adipocytes, in 
parallel with induction of adipogenic gene expression (Gurriarán-Rodríguez et al., 2011b; Ren 
et al., 2013a). However, obestatin-induced proliferation of 3T3-L1 preadipocytes was not 
associated with adipogenesis (Ren et al., 2013b). A similar investigation in porcine 
preadipocytes found obestatin to stimulate proliferation and differentiation and to inhibit 
apoptosis via promotion of peroxisome proliferator-activated receptor (PPAR)γ and CCAAT-
enhancer-binding protein (C/EBP)α and inhibition of caspase-3/7/9 (Tang et al., 2014). 
Consistent with these findings, isoproterenol-induced lipolysis in both 3T3-L1 preadipocytes 
and human subcutaneous and omental adipocytes was reduced by obestatin, with cells from 
obese subjects also demonstrating this obestatin response under basal conditions (Granata et 
al., 2012). In contrast, in isolated rat adipoctyes, obestatin has been shown to inhibit lipogenesis 
and potentiate adrenaline-induced lipolysis (Pruszynska-Oszmalek et al., 2013), although it also 
had no effect on 3T3-L1 preadipocyte glycerol release (Ren et al., 2013b). Recently, obestatin 
has been demonstrated to promote preadipocyte differentiation, lipid accumulation and leptin 
secretion, whilst decreasing and increasing lipolysis during differentiation and adipogenesis, 
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respectively (Wojciechowicz et al., 2015), indicating that the actions of obestatin in these 
settings may be complex.  
Effects of obestatin on both tissue and circulating lipid levels have also been widely 
investigated. For example, acute obestatin treatment in 3T3-L1 differentiating mouse 
adipocytes increased triglyceride levels (Miegueu et al., 2011), although circulating 
concentrations were reduced in rats or mice subjected to chronic treatment with native or 
modified obestatin, with activation of glycerolipid metabolism and PPAR signalling proposed 
as a potential mechanism (Agnew et al., 2011; Nagaraj et al., 2014). Although circulating 
cholesterol levels remained unaltered in obestatin-injected rats, decreased expression of 
cholesterol transporter ABCA1 was demonstrated in bovine WAT further to obestatin treatment 
(Grala et al., 2010; Agnew et al., 2011). Consistent with beneficial actions of obestatin on lipid 
metabolism, phosphorylation of AMP activated protein kinase is reported to be increased by 
obestatin in 3T3-L1 adipocytes and human adipose tissue, whilst in human subcutaneous 
adipocytes this effect occurs in parallel with modulation of adiponectin and leptin expression 
(Granata et al., 2012). 
With regard to glucose metabolism, obestatin has been shown to inhibit glucose 
transport in isolated rat adipocytes and to downregulate glucose transporter type 4 (GLUT-4) 
in adipose tissue (Pruszynska-Oszmalek et al., 2013; Ren et al., 2013a). In contrast, glucose 
uptake is reported to be enhanced by obestatin in both 3T3-L1 and human subcutaneous 
adipocytes, together with increased translocation of GLUT-4 to the plasma membrane increased 
via upregulation of sirtuin 1, which is important in mediating the insulin response, and 
activation of key signalling pathways, including Akt, glycogen synthase kinase-3β (GSK-3β), 
mechanistic target of rapamycin (mTOR), and ribosomal protein S6 kinase 1 (SK61) (Granata 
et al., 2012). Similar data have been generated by other groups upon investigation of WAT from 
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obestatin treated animals (Gurriarán-Rodríguez et al., 2011b), suggesting that obestatin is likely 
to activate, rather than inhibit glucose metabolism in adipose tissue. 
 
Obestatin in obesity and diabetes  
Although the precise metabolic actions of obestatin are still to be defined, it appears to 
play an important role with clear potential relevance to obesity and diabetes. Indeed, circulating 
levels of obestatin have been widely measured in this setting in both animals and humans 
(summarised in Table 2). Similar to the physiological situation, the data have been somewhat 
inconsistent (likely due to the reasons previously discussed), although it seems that obestatin 
levels are generally altered in diabetes and obesity. For example, decreased circulating obestatin 
has been documented in overweight/obese patients, and those with impaired glucose control, 
metabolic syndrome, T2DM and insulin resistance (Anderwald-Stadler et al., 2007; Qi et al., 
2007; Fontenot et al., 2007; Guo et al., 2007; Gao et al., 2008, 2010; Huda et al., 2008; Nakahara 
et al., 2008; Zou et al., 2009; Beasley et al., 2009; Cui et al., 2012; Shen et al., 2013; Gu et al., 
2013; Wang et al., 2014). Inverse correlations between circulating obestatin and body mass 
index, insulin, glucose, leptin, homeostatic model assessment of insulin resistance (HOMA-IR) 
and glycated haemoglobin have also been reported (Lippl et al., 2008; Nakahara et al., 2008; 
Gu et al., 2013; Shen et al., 2013; Wang et al., 2014), with reduced numbers of obestatin-
positive cells evident in the gastric mucosa of overweight/obese subjects with abdominal 
obesity (Gao et al., 2010, 2014). Similarly, in the experimental setting, obestatin is reported to 
decrease with insulin administration in normoglycaemic rats (Huang et al., 2012). Consistent 
with these data, obestatin levels increased with body weight reduction following gastric banding 
and sleeve gastrectomy surgery in obese and T2DM patients, respectively, and with standard 
weight loss in obese children (Haider et al., 2007; Arrigo et al., 2012; Lee et al., 2013). 
Obestatin levels were also higher in individuals with anorexia nervosa (Harada et al., 2008; 
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Monteleone et al., 2008a, 2008b; Germain et al., 2009, 2010; Sedlácková et al., 2011; Uehara 
et al., 2011; Sedlackova et al., 2012; Shen et al., 2013), and whilst they were decreased with 
hypothyroidism (associated with weight gain) they were  increased with hyperthyroidism 
(associated with weight loss) (Emami et al., 2014). Interestingly, the combination of 
preproghrelin polymorphisms Leu72Met and Gln90Leu have been associated with increased 
risk of anorexia nervosa (Dardennes et al., 2007). 
Although the majority of studies appear to support an inverse relationship between 
circulating obestatin and obesity/diabetes, increased obestatin levels have also been reported in 
patients with obesity, metabolic syndrome, impaired glucose control, T1DM, Prader-Willi 
syndrome (which is linked with obesity), and bulimia nervosa (Butler and Bittel, 2007; 
Vicennati et al., 2007; Reinehr et al., 2008; Sedlácková et al., 2011; Arrigo et al., 2012; 
Sedlackova et al., 2012; Mora et al., 2013; Prodam et al., 2014; Wali et al., 2014), whilst levels 
have been shown to be decreased in hyperthyroidism and in pregnant women 24 hours 
postpartum (which typically increases insulin sensitivity) (Baykus et al., 2012; Gurgul et al., 
2012). Other studies have found obestatin levels to be unaltered following gastric surgery-
induced weight loss in both obese and T2DM patients (Roth et al., 2009; Lee et al., 2013; Siejka 
et al., 2013) and in bulimia nervosa (Monteleone et al., 2008b). 
Of direct relevance to diabetes, obestatin levels were recently reported to be negatively 
correlated with the presence of c-peptide and anti-insulin antibodies in children at T1DM 
disease onset, which may therefore be indicative of islet dysfunction (Prodam et al., 2014). 
Consistent with a link between obestatin and the pancreas in diabetes, a study using rodent islets 
incubated in high glucose demonstrated differential effects of obestatin on insulin release, with 
low concentrations exerting a stimulatory effect whilst high concentrations were inhibitory, 
thereby suggesting that β-cells may be less responsive to obestatin in diabetes (Egido et al., 
2009). Obestatin treatment has also been shown to confer protective actions in experimental 
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streptozotocin-induced diabetes, specifically preservation of islet size and β-cell mass together 
with stimulation of insulin secretion, improved glucose tolerance and reduced blood glucose 
(Granata et al., 2010b). Similarly, insulin sensitivity and glucose tolerance were improved in 
obestatin-treated mice fed either a standard or high fat diet, with comparable effects on glucose-
induced insulin secretion observed in islets isolated from these animals (Granata et al., 2012). 
Furthermore, ex vivo adipose tissue analysis revealed enhanced glucose uptake, reduced 
lipolysis and apoptosis, in addition to increased abundance of smaller adipocytes (likely to be 
insulin-sensitive), particularly in subcutaneous adipose tissue. The observed beneficial effects 
of obestatin in this setting were associated with reduced production of pro-inflammatory 
cytokines e.g. tumour necrosis factor-α (TNF-α), highlighting apparent anti-inflammatory 
actions, at least in experimental diabetes (Granata et al., 2012). 
Considering the reasonably consistent alteration of circulating levels of obestatin in 
patients with metabolic disease (the majority of which display reduced concentrations), together 
with its established actions on the GI system, pancreas and adipose tissue, and emerging 
evidence supporting beneficial effects of obestatin treatment in experimental T1DM and 
T2DM, it is clear that this peptide demonstrates vast potential as a novel therapeutic target 
which is worthy of further investigation in the context of metabolic dysfunction linked with 
obesity and diabetes. 
 
CARDIOVASCULAR ACTIONS OF OBESTATIN 
In addition to the ascribed metabolic actions of obestatin, it is becoming increasingly 
evident that it may also exert important effects on the cardiovascular system. This is perhaps 
not surprising given the established cardiovascular actions of its sister hormone, ghrelin 
(Tokudome et al., 2014). Here, we highlight emerging effects of obestatin on the cardiovascular 
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system, with clear relevance to its more widely-studied metabolic actions in the context of 
diabetes which often leads to cardiovascular complications. 
 
Obestatin and blood pressure regulation 
Accumulating data support a relationship between circulating obestatin levels and blood 
pressure. However, the nature of this interaction has been differentially reported, similar to the 
previously discussed findings in regard in metabolic disease, which is frequently associated 
with hypertension. Fasting plasma obestatin levels were first reported to be negatively 
correlated with systolic blood pressure in insulin-resistant patients (Anderwald-Stadler et al., 
2007), findings which were later corroborated in patients with mild-to-moderate untreated 
essential hypertension in association with reduced ghrelin and ghrelin/obestatin ratio (Li et al., 
2010b), and in hypertensive versus normotensive obese patients (Wang et al., 2014). However, 
a study conducted in patients with pulmonary arterial hypertension found that circulating 
obestatin levels tended to increase, whilst the ghrelin/obestatin ratio was decreased compared 
with controls, and identified as an independent disease predictor (Li et al., 2013). Similarly, 
spontaneously hypertensive rats demonstrated increased fasting obestatin levels, although in 
this case ghrelin and the ghrelin/obestatin ratio were also elevated (Li et al., 2010a). 
Furthermore, in both normal pregnancy and those associated with hypertension (which is linked 
with hyperinsulinaemia and insulin resistance), plasma obestatin was positively correlated with 
mean arterial blood pressure, with the hypertensive group showing markedly higher levels 
versus normotensive controls, with these differences resolving within 3-5 days post-delivery 
(Ren et al., 2009). Indeed, the same study reported no correlation between mean arterial blood 
pressure and circulating obestatin in non-pregnant women. Other studies investigating the 
relationship between obestatin levels and blood pressure in men over 80 years of age and effects 
of bolus obestatin adminstration in spontaneously hypertensive rats administered have failed to 
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produce positive findings (Li et al., 2009; Shao et al., 2014). As previously highlighted, there 
appear to be fundamental issues with measurement of obestatin levels, which may relate to 
differences in detection or sensitivity, but are also likely to be influenced by physiological 
factors such as feeding state and diurnal variation, which consequently make the available data 
difficult to interpret. Nonetheless, the clinical and experimental studies to date would generally 
suggest that obestatin plays some role in blood pressure regulation, although standardisation 
and refinement of the employed plasma analysis techniques is clearly required in order to define 
the precise nature of any interaction. 
 
Obestatin and endothelial function in health and disease 
Although the specific relationship between obestatin and blood pressure remains to be 
determined, more definitive evidence is emerging in support of beneficial actions on the 
endothelium, which plays a major role in both blood pressure regulation and protection against 
the development of diabetic cardiovascular complications, suggesting that it may represent a 
viable therapeutic target in this setting. Obestatin was first reported to exert direct anti-
inflammatory effects on human EA.hy926 endothelial cells, by decreasing TNF-α-induced 
vascular cell adhesion molecule-1 (VCAM-1) expression, whilst not influencing associated 
monocyte adhesion or monocyte chemoattractant protein-1 (MCP-1) expression (Kellokoski et 
al., 2009). However, the same study found obestatin to also promote binding of oxidised low-
density lipoprotein (LDL) to thioglycollate-stimulated mouse peritoneal macrophages, thereby 
suggesting that it may mediate differential modulation of early atherogenic processes. Obestatin 
can also bind to microvascular endothelial cells in pancreatic islets and promote survival and 
proliferation of these cells under high glucose conditions by inhibiting caspase-3, Akt and 
ERK1/2-dependent apoptosis pathways, effects which were interestingly prevented by the 
GLP-1R antagonist, exendin(9-39) (Favaro et al., 2012). Recently, several groups have reported 
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that obestatin induces vascular relaxation, both ex vivo and in vivo in a nitric oxide (NO)-
dependent manner (Agnew et al., 2012; Ku et al., 2015; Schinzari et al., 2015). First, obestatin 
was shown to induce dose-dependent relaxation of isolated rat aorta and superior artery, which 
was inhibited by both endothelial denudation and the NO inhibitor, L-NMMA (Agnew et al., 
2012). Comprehensive ex vivo analysis identified a pathway involving an adenylate cyclase-
linked G protein-coupled receptor, PI3K/Akt and Ca2+-dependent endothelial NO synthase 
activation, coupled to downstream vascular smooth muscle soluble guanylate cyclase and large 
conductance calcium-activated potassium channel (BKCa) activation (Agnew et al., 2012; see 
manucript for a detailed signalling schematic). Similar findings have since been reported in 
mouse cerebral artery, in which obestatin-induced vasodilation was shown to be endothelial 
NO synthase-dependent and maintained in both the presence of the ghrelin receptor antagonist 
YIL-781 and vessels from ghrelin receptor-deficient mice (Ku et al., 2015). Interestingly, basal 
NO bioactivity was markedly reduced in mice lacking the ghrelin receptor together with 
elevated superoxide generation, highlighting potential protective actions of obestatin in the 
cerebral circulation. Importantly, the reported ex vivo vascular effects of obestatin appear to 
translate to humans. A recent study reported induction of NO-dependent vasodilation (as 
assessed by increased forearm blood flow) in both obese and non-obese subjects, which was 
associated with inhibition of endothelin-1 signalling (Schinzari et al., 2015). Furthermore, it 
seems that obestatin may also exert notable actions on the microvasculature, which is a major 
regulator of blood pressure. Specifically, hyperglycaemia-induced generation of nitrite (stable 
oxidation product of NO), vascular endothelial growth factor (VEGF), and pro-inflammatory 
interleukin-1β, in pancreatic microvascular endothelial cells were attenuated by obestatin, 
whilst obestatin improved mouse skeletal muscle regeneration via stimulation of 
microvascularisation secondary to induction of satellite stem cell expansion and VEGF/VEGF 
receptor 2 expression (Favaro et al., 2012; Gurriarán-Rodríguez et al., 2015). Taken together, 
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these data clearly indicate that obestatin may play a role in both normal regulation of blood 
pressure and vascular function, and in the setting of diabetes, which is characterised by 
endothelial dysfunction and reduced NO production, and frequently associated with 
cardiovascular complications. 
 
Obestatin and the heart 
In addition to its emerging vascular effects, it appears that obestatin may exert both 
direct and indirect actions on the heart. Shortly after its discovery, obestatin was shown to bind 
specifically to GPR-39 on HL-1 cardiomyocytes, although no parallel acute effects on cell 
viability, cell cycle or fatty acid/glucose uptake were observed (Iglesias et al., 2007). Obestatin 
was later reported to reduce infarct size and contractile dysfunction in isolated rat hearts 
subjected to ischaemia-reperfusion by conferring dose-dependent protection against cell death 
via activation of PI3K, protein kinase C (PKC)-ε, PKC-δ, and ERK1/2 pathways (Alloatti et 
al., 2010). Notably, this study also employed radioreceptor binding assays to highlight the 
presence of specific high-affinity obestatin-binding sites localised on the membranes of both 
the ventricular myocardium and cardiomyocytes, supporting the assertion that obestatin 
receptors are expressed in the heart. Similarly, obestatin improved basal papillary muscle 
contractility and responsiveness to β-adrenergic stimulation in streptozotocin-induced T1DM 
rats, but not in non-diabetic controls, via protection against loss of β-adrenoreceptors and rescue 
of myosin heavy chain isoforms (Aragno et al., 2012). These findings are consistent with a 
previous observation that topical obestatin administration induces positive inotropic effects in 
frog hearts ex vivo (Sazdova et al., 2009). In the clinical setting, there appears to be no 
correlation between ischaemic heart disease and plasma obestatin (Ozbay et al., 2008). 
However a clear tendency towards increased plasma obestatin levels in chronic heart failure 
patients is observed, which becomes significant in those with cachexia, whilst elevated 
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circulating concentrations of both obestatin and vasopressin are associated with cardio-renal 
syndrome (Xin et al., 2009; Shi et al., 2012). Indeed, obestatin is reported to inhibit 
experimental angiotensin II and dehydration-induced release of vasopressin (Samson et al., 
2007, 2008), which is a key regulator of physiological fluid/electrolyte balance implicated in 
heart failure progression (Goldsmith and Gheorghiade, 2005; Wasilewski et al., 2015). 
Although current data supporting direct cardiac effects of obestatin may be limited, such actions 
are likely to be significant given the established structural and functional changes which occur 
in diabetes and are linked to markedly increased susceptibility to hypertension and ischaemia 
(Bugger and Abel, 2014). 
 
SUMMARY AND FUTURE PERSPECTIVE 
 It is becoming increasingly evident that obestatin exerts wide-ranging metabolic and 
cardiovascular actions with clear relevance to the pathophysiology of diabetes and obvious 
therapeutic potential (summarised in Figure 1). Whilst the precise effects of both endogenous 
and exogenous obestatin in this setting remain to be determined, the attraction of a dual action 
therapeutic targeting both the metabolic and cardiovascular complications of diabetes is clear, 
particularly in light of the recent large-scale clinical trial data suggesting that the cardiovascular 
actions of the established T2DM therapy, GLP-1, which showed vast cardiovascular potential, 
may not be clinically significant (Scirica et al., 2013; White et al., 2013). In recognition of this 
fact and the emerging actions of obestatin, several groups have focussed on characterising and 
maximising its biological activity. 
Interestingly, it appears that differential domains of obestatin may preferentially 
mediate its metabolic and cardiovascular effects. For example, obestatin(1-4) is reported to 
decrease food intake, body weight, and plasma total antioxidant capacity in rats, and to 
modulate blood glucose (Khirazova et al., 2013, 2015; Motorykina et al., 2015), whilst in mice, 
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obestatin(1-13) reduced food intake, body weight gain and circulating lipids and obestatin(6-
18) decreased epididymal fat and triglycerides to a greater extent versus native obestatin, 
(Nagaraj et al., 2008). Conversely, administration of the C-terminal fragment, obestatin(11-23), 
to high fat-fed mice resulted in equivalent reductions in food intake and postprandial glucose 
levels compared to the full-length peptide, while the N-terminal fragment, obestatin(1-10) 
failed to induce metabolic changes in this setting (Green et al., 2007; Subasinghage et al., 2010). 
With regard to its cardiovascular effects, although both obestatin(1-10) and obestatin(11-23) 
induced dose-dependent ex vivo vasodilatation, this was significantly reduced compared with 
obestatin(1-23) (Agnew et al., 2012). 
Similar to the approach taken with regard to therapeutic advancement of GLP-1, a major 
focus of recent obestatin research has been directed towards development of stable obestatin 
peptides which are resistant to endogenous degradation. Indeed, several such analogues based 
on N-terminal PEGylation, amino acid substitution, and iodination strategies demonstrate 
significantly improved stability and bioactivity (Nagaraj et al., 2009; Agnew et al., 2011; De 
Spiegeleer et al., 2012). For example, chronic treatment of normal rats with N-terminally 
PEGylated obestatin, but not native obestatin, markedly reduced triglyceride levels (Agnew et 
al., 2011), and amino acid substitutions of obestatin(1-13) and obestatin(6-18) conferred 
variable favourable actions on food intake, body weight, epididymal fat, and total cholesterol 
in mice, together with activation of key metabolic signalling pathways (Nagaraj et al., 2009, 
2014). Interestingly, an alternate obestatin modification approach involving TAT peptide fusion 
to promote cell permeability has reported greater inhibition of in vitro apoptosis and increased 
glycerol/free fatty acid release in 3T3-L1 human preadipocytes compared with native obestatin, 
whilst chronic treatment in mice decreased abdominal fat mass, together with modulation of 
key metabolic genes, such as adiponectin and GLUT-4, in liver and WAT (Ren et al., 2013a). 
Taken together, these preliminary studies provide some confidence that, at least in principle, it 
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may be possible to effectively target obestatin signalling in humans. Given its increasingly 
evident metabolic and cardiovascular actions, it is clear that obestatin holds potential as a viable 
and novel dual treatment strategy for diabetes patients. 
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FIGURE LEGEND 
Figure 1  Summary of the reported pathophysiological effects of obestatin. Obestatin targets 
several tissues, including the gastrointestinal system, pancreas, white adipose tissue, the heart 
and vasculature, where it exerts diverse biological actions relevant to the metabolic and 
cardiovascular complications of diabetes.  
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TABLE 1: Circulating levels of obestatin in normal physiology 
 
 
 
EIA, enzyme immunoassay; RIA, radioimmunoassay. aMean ± SEM, bMean ± SD, cMean ± SEM or 
Mean ± SD, dMedian, eMedian (Interquartile range), fMedian (1st -4th quartile), gMedian (min-max).
Obestatin Level (pg/ml) 
Study Details 
Tissue Detection Reference 
24.9 ± 3a Plasma (Human ♂/♀) Unknown Huda et al., 2007 
139.3 ± 46.8b Plasma (Human ♂/♀) RIA Lippl et al., 2008 
438.9 ± 350.7b Serum (Human ♂/♀) RIA Koca et al., 2008 
181 ± 15.3a Plasma (Human ♀) RIA Sedlácková et al., 2008 
270.3 ± 28.21b Blood (Human ♀) RIA Aydin et al., 2008 
63.4 ± 9.5b Plasma (Human ♀) RIA Ren et al., 2009 
227.8 ± 116.9b Serum (Human ♂/♀) RIA Aygen et al., 2009 
148.2 ± 96.8b Plasma (Human ♂/♀) RIA Kukuvitis et al. 2010 
4600 ± 1600b Serum (Human ♂/♀) EIA Mafra et al., 2010 
364.9 ± 101.4c Plasma (Human child ♂/♀) Unknown Buescher et al., 2010 
1156.1 ± 1361.8b Serum (Human ♂/♀) RIA Gutierrez-Grobe et al., 2010 
32.5 ± 5b Plasma (Human ♂/♀) RIA Kosowicz et al., 2011 
243.5 ± 65.37b Serum (Human ♂) RIA Moretti et al., 2011 
3600d Serum (Human ♂/♀) EIA Aktas et al., 2011 
844.87 (805.14)e Serum (Human infants ♂/♀) RIA Savino et al., 2012 
205 ± 48b Plasma (Human ♀) EIA Hedayati et al., 2012 
2674 (2343-4890)f Plasma (Human ♂/♀) RIA Grönberg et al., 2013 
3663.90 ± 2313.95b Plasma (Human ♂/♀) EIA Lei et al., 2014 
58.5 ± 10.3b Serum (Human ♂/♀) EIA Emami et al., 2014 
410.72 ± 115.44b Plasma (Human ♂/♀) EIA Liu et al., 2014 
69.7 ± 7.5b Plasma (Human ♂/♀) RIA Gao et al., 2014 
21.68 ± 1.42b Serum (Human child ♂/♀) EIA Taskin et al., 2014 
325.3 ± 163.6b Serum (Human child ♂/♀) RIA Saliakelis et al., 2014 
200 ± 20b Plasma (Human infants ♂/♀) RIA Zhang et al., 2014 
8.4 (1.9–13.0)g Serum (Human ♀) EIA Taskin et al., 2015 
22057 ± 873a Serum (Human ♂/♀) EIA Ayada et al., 2015 
805 ± 30a Plasma (Mouse/Rat ♂) RIA Zizzari et al., 2007 
Below detection limit Plasma (Rat ♂) RIA Mondal et al., 2008 
1680 ± 100a Plasma (Rat ♂) EIA Guo et al., 2008 
2560 ± 120a Plasma (Rat ♂) EIA Ghanbari-Niaki et al., 2010 
1800 ± 180a Plasma (Rat ♂) EIA Huang et al., 2012 
1.34 ± 0.1c Serum (Rat ♂) RIA Kong et al., 2010 
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TABLE 2: Effect of disease pathology on circulating levels of obestatin 
 
 
AXN, anorexia nervosa; BMN, bulimia nervosa; CHF, chronic heart failure; CRS, cardiorenal syndrome; DB, diabetes, EIA, enzyme immunoassay; HTN, 
hypertension; IHD, ischaemic heart disease; IR, insulin resistance; OB, obesity; PWS, Prader-Willi Syndrome; PE, preeclampsia; RIA, radioimmunoassay. 
aMean ± SEM, bMean ± SD, cMean ± SEM or Mean ± SD. 
Obestatin Level (pg/ml) 
Ghrelin/Obestatin ↑↓ 
Study Details 
Normal Physiology Disease Pathology Tissue Detection Reference 
160  100 (OB) - Serum (Human ♀) RIA Fontenot et al., 2007 
70.5±6.4b 42.6±9.8b (OB) OB ↑ Plasma (Human ♂/♀) RIA Guo et al, 2007 
325±109b 398±102b  (OB, PWS) - Plasma (Human ♂/♀) RIA Butler and Bittel 2007 
- - OB ↓ Plasma (Human ♀) RIA Vicennati et al., 2007 
27.8±4.0a 17.2±2.0a (OB) - Plasma (Human ♂/♀) RIA Huda et al., 2008 
72.3±8.9a 55.6±6.4a (OB) - Plasma (Human ♂) RIA Gao et al., 2008 
267.9±10.8a 201±12, 298±17a (OB, AXN) OB, AXN ↑ Plasma (Human ♀) RIA Zamrazilová et al., 2008 
0.15±0.01a 0.12±0.01, 0.20±0.01a (OB, AXN) - Plasma (Human ♀) RIA Nakahara et al., 2008 
69.7±7.5b 52.9±7.9b (OB) - Plasma (Human ♂/♀) RIA Gao et al., 2010 
228±60b 212±44b (OB) OB ↓ Plasma (Human child ♂/♀) RIA Zou et al., 2009 
- 288±104b (OB) OB ↓ Plasma (Human child ♂/♀) RIA Reinehr et al., 2008 
- - OB, AXN ↑ Blood (Human child ♂/♀) EIA Shen et al., 2013 
2803±939c 3670±1336c (OB) OB ↓ Plasma (Human child ♂/♀) EIA Wali et al., 2014 
1870±590b 2030±510b (OB) OB ↓ Serum (Human elderly ♀) EIA Mora et al., 2013 
49.2±2.2a 64.5±2.2a  (AXN) - Plasma (Human ♀) RIA Harada et al., 2008 
82.5±29.3b 130±17b (AXN) - Plasma (Human ♀) EIA Monteleone et al., 2008a 
68.3±14.8b 86.2±24.4, 74.9±22.4b (AXN, BMN) AXN ↑ Plasma (Human ♀) EIA Monteleone et al., 2008b 
288±26a 393±25a (AXN) - Plasma (Human ♀) RIA Germain et al., 2009 
48.4±11.2a 72.6±7.0a  (AXN) - Plasma (Human ♀) RIA Uehara et al., 2011 
325±26a 276±15a (HTN) HTN ↓ Plasma (Human ♂) RIA Li et al., 2010b 
4720±820c 5060±680c (HTN) - Plasma (Human ♂) EIA Shao et al., 2014 
474±43b 338±67, 283±75b (OB, HTN) OB, HTN ↑ Plasma (Human ♂/♀) RIA Wang et al., 2014 
38.6±1.5a 44.6±2.3a (HTN) HTN ↑ Plasma (Rat ♂) RIA Li et al., 2010a 
436.4±114b 435±127b  (IHD) - Serum (Human ♂/♀) RIA Ozbay et al., 2008 
162±12b 163±9b  (CHF) CHF ↓ Plasma (Human ♂/♀) RIA Xin et al., 2009 
212±38b 356±85b  (CRS) - Plasma (Human ♂/♀) EIA Shi et al., 2012 
224±19b 276±15b (PE) PE ↓ Serum (Human pregnant ♀) RIA Wu et al., 2015 
469±23b 383±26b  (IR) - Plasma (Human ♂/♀) RIA Anderwald-Stadler et al., 2007 
43.8±1.4b 37·4±1.3b  (DB) - Plasma (Human ♂/♀) RIA Qi et al., 2007 
- 257±10a (DB) - Plasma (Human ♂/♀) RIA Harsch et al., 2009 
301±35a 267±17a  (DB) - Blood (Human ♂) RIA St-Pierre et al., 2010 
5072±608a 7203±615a (DB) - Plasma (Human child ♂/♀) EIA Prodam et al., 2014 
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